Total synthesis of structurally-diverse pleuromutilin antibiotics

Olivia Goethe[1], **Mikaela DiBello**[1], **Seth B. Herzon**[1,2]

[1]Department of Chemistry, Yale University, New Haven, Connecticut 06520, United States.

[2]Department of Pharmacology, Yale School of Medicine, New Haven, Connecticut 06520, United States.

Abstract

The emergence of drug-resistant bacterial pathogens has placed renewed emphasis on the total chemical synthesis of novel antibacterials. Tetracyclines, macrolides, streptogramins, and lincosamides are now accessible by flexible and general synthetic routes. Pleuromutilins, antibiotics based on the fungal metabolite pleuromutilin, have remained resistant to this approach, in large part because of the difficulties encountered in the de novo construction of the decahydro-3a,9-propanocyclopenta[8]annulene skeleton. Here we present a platform for the total synthesis of pleuromutilins that provides access to diverse derivatives bearing alterations at skeletal and peripheral positions that were previously inaccessible. The synthesis is enabled by the serendipitous discovery of a vinylogous Wolf rearrangement, which serves to establish the C9 quaternary center in the targets, and the development of a highly diastereoselective butynylation of an α-quaternary aldehyde, which forms the C14 secondary alcohol. The versatility of the route is demonstrated through the synthesis of seventeen structurally-distinct derivatives, many possessing potent antibacterial activity.

Editorial Summary:

General synthetic methods to access pleuromutilin antibiotics are limited because of their complex carbocyclic skeleton. Now, a synthetic platform has been developed to access structurally diverse pleuromutilins with variations at the quaternary C12 position and hydrindanone cores. Seventeen structurally-distinct derivatives were prepared and evaluated against a panel of Gram-positive and Gram-negative bacteria.

Pleuromutilins[1–2] inhibit protein synthesis by binding the peptidyl transferase center (PTC) of the bacterial ribosome. The carbocyclic skeleton and C14 extensions occupy the A- and P-sites of the PTC, respectively.[3] Variations of the glycolic ester increase potency in Gram-positive pathogens (GPPs).[1–2] Alternatively, "extended spectrum pleuromutilins" (ESPs, see **5**, Fig. 1a) are formed by the introduction of polar substituents at the C12 pseudoequatorial position[4] (by an unusual epimerization of C12).[5] ESPs possess activity against Gram-negative pathogens (GNPs), including carbapenem-resistant *Enterobacteriaceae*[6] and drug-

resistant *Neisseria gonorrhoeae*,[7] strains identified as Urgent Threats by the US CDC. Pleuromutilins bind the PTC by a unique conformation[3] and do not display cross-resistance with other antibiotics.[2] Moreover, they are durable:[8] three stepwise mutations in the ribosomal protein L3 are required for resistance, but each mutation induces a fitness defect.[9] The class is limited by low oral bioavailability and cytochrome P450 oxidation at C8,[10–12] which leads to deactivation.

Retapamulin (**3**)[13] and lefamulin (**4**)[14] are clinical semisynthetic agents. While other classes of antibiotics, such as the tetracyclines[15], macrolides[16], streptogramins[17], and lincosamides,[18] are now accessible by flexible, high-yielding, and fully synthetic routes, pleuromutilins are less-well developed.[19–24] Advanced derivatives were prepared by Sorensen and co-workers[25] but their activity was modest. We reported a synthesis of (+)-pleuromutilin (**1**) and its 12-*epi*-derivative (**2**).[22] A Nagata hydrocyanation[26] of the hydrindenone **6** established the C9 stereocenter, and a two-fold neopentylic fragment coupling joined the eneimide **8** and an organolithium reagent derived from the alkyl iodide **9** (Fig. 1b). Unfortunately, the hydrocyanation of **6** was not general, the scope of the fragment coupling was narrow, and the introduction of the C14 stereocenter after formation of the eight-membered ring was challenging.[22–23] Elaboration of the fragment coupling product **10** to (+)-pleuromutilin (**1**) proceeded in 11 steps and 4% yield (0.4% from cyclohexanone). These limitations motivated us to devise the new synthetic route presented herein. We sought to: a) develop alternative methods to establish the C9 and C14 stereocenters; b) increase the generality of the route; c) increase overall yield; and d) move branch points later in the synthesis. Because modifications to the C12 axial position in (+)-pleuromutilin (**1**) have a negligible effect on activity,[4, 27] and 12-normethyl derivatives adopt the same conformation as (+)-pleuromutilin (**1**; Fig. 2f) we targeted 12-noralkyl pleuromutilins, an approach that simplifies synthetic planning.

Results and Discussion.

Synthesis of a diversifiable advanced intermediate.

The first goal (a) was addressed by the discovery of a vinylogous Wolff rearrangement of the α-diazoketone **11** (Fig. 2a). Thus, the expected homologation product **12** and the rearranged ester **13** were obtained in 47% and 50% yield, respectively, when the α-diazoketone **11** was subjected to Arndt–Eistert homologation conditions (silver acetate, methanol). The structure of **13** was confirmed by X-ray analysis of the corresponding carboxylic acid (Fig. S8) and the products **12** and **13** are readily separable by flash-column chromatography (R_f of **13** and **12** = 0.83 and 0.67, respectively, in 50% ethyl acetate–hexanes). The transformation may proceed by a concerted [2,3]-rearrangement with loss of dinitrogen (**11**→**14**→**15**), or an intramolecular cyclopropanation–fragmentation pathway (**11**→**16**→**17**→**15**, Fig. 2b). This is the first vinylogous Wolff rearrangement[28] reported for an electron-deficient π-system. Though we were not able to increase the ratio of **13**:**12**, this rearrangement provided a stereospecific method to establish the C9–C10 bond in the target and provided reliable results on a multigram scale. Of greater significance, this rearrangement proved tolerant to several different ring sizes and substituents and was applied to other bicyclic ketones, leading to novel pleuromutilin structures (Figs. 3, 4).

Treatment of the rearrangement product **13** with diethylaluminum cyanide provided the 1,4-hydrocyanation product **18** in 98% yield and as a single detectable C5 diastereomer (^{1}H NMR analysis, Fig. 2c), a result consistent with earlier findings by Sorensen and co-workers.[25] Protection of the ketone[22] provided the expected glycol ketal (not shown). The methylation product **19** was obtained as a single detectable diastereomer (^{1}H NMR analysis) by deprotonation of the ester (lithium diisopropylamide, LDA), followed by the addition of iodomethane (85% from **18**). The relative stereochemistry of **19** was secured by X-ray analysis. We reason that the (*Z*)-enolate[29] **25** may adopt the conformation shown in Fig. 2d, which minimizes 1,3-diaxial interactions with the axial C7 and C9 substituents. Approach of iodomethane from the less hindered β-face would provide the observed product. Reduction of the nitrile and ester residues (diisobutylaluminum hydride, DIBALH) generated the hydroxyaldehyde **20** (96%), which constitutes our first point of divergence (10 steps, 15% overall from cyclohexenone).

We then focused on establishing the C14 stereocenter before formation of the eight-membered ring. We initially evaluated the butynylation of **20**, as this would provide the correct functional group handles for later steps (Table S1). The product **21** was obtained in 30–33% yield and as predominantly the undesired (14*S*) diastereomer when butynylmagnesium bromide was used as the nucleophile in ethereal solvents. After evaluating a large number of conditions, we found that the desired diastereomer (14*R*)-**21** was formed with >20:1 stereoselectivity by titanocene-mediated addition of 1-bromo-but-2-yne,[30] although the yield was only 21%. Further optimization provided the desired (14*R*) diastereomer in 81% and with 37:1 diastereoselectivity. The alternating, reagent-controlled stereoselectivities in this addition are notable. The addition of propargyl magnesium reagents may proceed by chelation between the Grignard species and the hydroxyaldehyde **20**;[31] addition to the less-hindered α-face would provide the (14*S*) diastereomer. The stereoselectivity in the titanocene-mediated pathway is thought to arise from a closed six-membered transition state between an allenyl-titanium reagent and the aldehyde within **20**.[32] Notably, the titanocene-mediated pathway was singularly successful; all other approaches examined returned starting material, likely due to the hindered nature of the α,α,α-trisubstituted aldehyde. The addition proved to be relatively general for a series of related nucleophiles (Fig. 3a). The yields and stereoselectivities were largely insensitive to alkyne substitution, and the reaction was tolerant of heteroatom- and halogen-substituted reagents. The scope of this reaction provided additional functional group handles for diversification of the C12 position following formation of the eight-membered ring (Figs. S5–S7).

Selective oxidation of the primary alcohol within **21** (2-iodoxybenzoic acid, IBX[33]) and *exo*-selective nickel-catalyzed reductive cyclization[34–35] formed a cyclization product (not shown) as a single detectable C11 diastereomer (^{1}H NMR analysis, Fig. 2c). Introduction of the glycolic acid residue and removal of the silyl ether (hydrogen fluoride–pyridine complex) generated the ester **23** (69% over four steps). Directed hydrogenation (Crabtree's catalyst[36]), sulfonate displacement, and ketal cleavage provided the pleuromutilin derivative **24** (49% overall). The complete relative stereochemistry of **24** was determined by X-ray analysis of the saponification product **26** (Fig. 2e). A molecular dynamics simulation (Merck molecular force field, MMFF)[37] confirmed that **24** and (+)-pleuromutilin (**1**) overlay without

discernable differences in conformation and positioning of the substituents required for hydrogen bonding contacts with the ribosome (Fig. 2f).[3] Because earlier structure–activity data revealed that the pseudoaxial C12 substituent does not influence antibacterial activity,[4] and the calculations suggest it does not bias the conformation of the molecule, we pursued 12-norvinyl derivatives as a means to simplify the synthetic route. By this approach, **23** was obtained in 10 steps and 17% yield from the hydrindenone **6**, a substantial improvement in efficiency over our route to 12-*epi*-pleuromutilin (**2**; 1.5% overall). The sulfonated glycolic ester facilitates diversification via nucleophilic displacement while the exocyclic alkene provides a handle for late-stage equatorial functionalization. To demonstrate the power of this approach, a derivative of the clinical agent lefamulin (**4**)[14, 38] was prepared in three steps from **23** by directed hydrogenation, sulfonate displacement with the thiol **36**, and acidic deprotection (40% overall, Fig. 3b).

Synthesis of core-modified pleuromutilins.

With a new and efficient synthetic pathway established, we focused on adapting this chemistry to the synthesis of pleuromutilins containing skeletal modifications that are inaccessible by semisynthesis. Because metabolic oxidation at C8 (Fig. 1) leads to antibiotic deactivation[39–40] we targeted derivatives that might be less susceptible to this pathway by blocking this position with an alkyl substituent (as in **45**, Fig 3c) or contracting the six-membered ring to render this site less accessible (as in **51**, **55**, and **56**, Fig. 4a). Both of these classes can be prepared from the common intermediate **38**, which is itself derived from (+)-pulegone in three steps and 58% yield.[41]

Palladium(II)-mediated oxidation of **38**[42] (palladium acetate, diethylallylphosphate, potassium carbonate)[43–44] provided the enone **39** (70%, Fig. 3c). Silicon-promoted, copper-catalyzed 1,4-addition[45] of methyllithium generated the 1,4-addition product **40** as a single diastereomer. The relative stereochemistry of the product was confirmed by X-ray analysis of a later intermediate. Cyclopropanation, followed by an iron(III) trichloride-mediated ring expansion,[46] elimination of hydrogen chloride, and hydrogenation with Pearlman's catalyst provided the cyclohexane **42** (43%, four steps). 1,2-Addition of the Grignard reagent derived from methyl propargyl ether followed by treatment with methanesulfonic acid formed the bicyclic enone **43** (77% overall), which was elaborated to the tricycle **44** in 10 steps (13% overall, see Fig. S1). The tricycle **44** was transformed to the C7-substituted lefamulin derivative **45** in five steps (25% overall, Fig. S1).

The synthesis of the ring-contracted derivatives began with 1,2-addition of the Grignard reagent derived from methyl propargyl ether to **38**, followed by acid-catalyzed rearrangement, to provide the bicyclo[3.3.0]octane derivative **46** (48%, two steps, Fig. 4a). The bicyclic ketone **46** was elaborated to the cyclization precursor **47** in 11 steps and 6% overall yield (Fig. S3). Reductive cyclization of **47** provided the tricyclic product **48** (70%) as a single detectable diastereomer (^{1}H NMR analysis). NOE analysis established that the (11*R*) diastereomer was formed. All attempts to cyclize the derivative of **47** containing a C10 methyl substituent were uniformly unsuccessful (Fig. S2). The tricyclic product **48** (70%) was elaborated to the glycolic ester derivative **49** in two steps (87% overall).

The ester **49** served as a branch point to prepare three distinct, ring-contracted analogs. Thus, directed hydrogenation, introduction of the lefamulin side chain, and acidic deprotection provided the (11*R*) derivative **51** (21% overall). The C11 center could be inverted under Mitsunobu conditions using picolinic acid as nucleophile.[47] Copper-catalyzed methanolysis then provided the (11*S*) derivative **52** (26% overall). Hydrogenation of **52** formed a ~1:1 mixture of (separable) C12 diastereomers. These were elaborated separately to the lefamulin derivatives **55** and **56**.

Finally, we prepared the derivative **59**, wherein the eight-membered ring is contracted by a single atom (Fig. 4b). We targeted this derivative to probe the significance of the location of the C11 hydroxyl in ribosome binding. Swern oxidation of **20**, followed by the site- and diastereoselective addition of lithium trimethylsilyl acetylide and cleavage of the silyl substituent (potassium carbonate, methanol) provided the propargylic alcohol **57** (64% overall). Reductive cyclization of **57** generated the allylic alcohol **58** (30%) as a single detectable C14 diastereomer (^{1}H NMR analysis, relative stereochemistry confirmed by NOE analysis). The cyclization product **58** was converted to the ring-contracted derivative **59** in six steps (3% overall, unoptimized, Fig. S4).

Synthesis of additional derivatives and evaluation of antibiotic activity.

In parallel to synthesizing the various tricyclic cores, we introduced late-stage modifications that are inaccessible by semisynthesis. For this objective, nine additional derivatives were prepared with modifications at the C12 equatorial position (Fig. 5 and Figs. S5–S7). We assessed the Minimum Inhibitory Concentrations (MICs) of these C12 derivatives and the agents bearing modified skeletons against a panel of Gram-positive and Gram-negative pathogens. Several derivatives had comparable potency to the clinically used lefamulin (**4**) and semisynthetic controls (**60–62**). The alkyl chloride **63** (prepared from the addition product **34**, Fig. S5) emerged as the most potent compound, with notable activity against methicillin-resistant *S. aureus* (0.25 μg/mL), methicillin and mupirocin-resistant *S. epidermidis* (0.12 μg/mL), and vancomycin-resistant *E. faceium* (0.25 μg/mL). It also exhibited potent activity towards *S. pyogenes* (0.03 μg/mL) and vancomycin-susceptible *E. faceium* (0.03 μg/mL). Analogs **64** and **65**, also derived from the alkyl chloride **34** via azide displacement and click chemistry, demonstrated comparable potency. Like lefamulin (**4**) and **63**, they are active against several vancomycin- and penicillin-resistant bacterial strains. The amine **65** also showed modest activity in *E. coli* 25922 (4 μg/mL) and the ESKAPE pathogen *K pneumoniae* (16 μg/mL), consistent with the notion that sterically-accessible, basic amines enhance activity in Gram-negative pathogens.[4, 48] Relative to the alkyl chloride **63**, **64** and **65** possessed modest activity (8 μg/mL) against the ABC-F transporter-expressing *E. faecalis*, suggesting a path forward to combat efflux. An axial, C12 diamine extension in the derivative **66** was also prepared from the enyne propargylation product **28**. The axial amine showed diminished antibiotic activity, emphasizing the strength of our sequence towards selectively preparing equatorial derivatives (Fig S6). In the first examples of heteroatom substituents at the C12 position of pleuromutilins, the two exocyclic epoxide derivatives **67** and **68** possessed moderate antibiotic activity across most of the Gram-positive isolates (0.5–2 μg/mL), suggesting the allylic alcohol in our sequence is a valuable starting point for further diversification. The exocyclic alkenes **69** and **70**

were nearly inactive, suggesting the conformation of the eight-membered ring is vital for cellular uptake or ribosome binding. The α-hydroxy ketone **71** derivative was also inactive, supporting hydrogen-bond donation by the C11 hydroxyl group as critical for ribosome binding.

A significant decrease in potency was observed when the C12 normethyl analog **37** was directly compared to lefamulin (**4**) and the semisynthetic control **60** (Fig. 5). This was surprising to us given the prior reports that modification of the C12 axial position has little effect on antibacterial activity,[4] and suggests the quaternary center could contribute to stability or hydrophobic contacts with the ribosome. The core-modified analogs **45**, **51**, **55**, **56** and **59** were inactive in all isolates tested except *H. influenzae,* where **45**, **51** and **56** had identical activity to lefamulin (**4**). The C7-substituted and ring contracted derivatives provide the first structure–activity data related to ring size and carbogenic substitution.

The inactivity of the glycolic acid side chain analog **24** highlighted the need to derivatize with a polar side chain in order to glean meaningful structure–activity insights. This is a strength of the synthetic route. For example, exchanging the side chain of the C12 normethyl compound to the benzamide diamine side-chain in **72**[4] (R^2, Fig. 5) improved potency across many of the Gram-positive strains tested. The derivative **72** had comparable activity to the corresponding semisynthetic control **61**, suggesting that further side chain modification could easily be performed to optimize the potency of the active C12 normethyl derivatives.

Conclusion.

We have developed a new platform to prepare fully synthetic pleuromutilin analogs with potent activity. The synthetic strategy, which proceeds through a novel, stereospecific Wolff rearrangement and highly diastereoselective addition of propargylic nucleophiles to an α-quaternary aldehyde, addresses the challenges identified in our previous synthesis and provides access to the late-stage, diversifiable intermediate **23** in 10 steps and 17% overall yield from the hydrindenone **6**, a significant improvement compared to 14 steps and 1.5% overall yield to the diversification point in the prior sequence, (+)-12-*epi*-pleuromutilin (**2**), from **6**. Perhaps more significantly, the route proved general and delivered seventeen structurally-diverse analogs including those possessing varying ring sizes and substituents at the C14, C12, and C7 positions. Several of the novel compounds prepared are potent against a variety of antibiotic-resistant pathogens and provide novel structure–activity insights into this class of molecules. The generality of the route, in conjunction with the ability to introduce novel pseudo-equatorial substituents, may lead to optimal compounds with potent Gram-positive and Gram-negative activity. Further development of core modifications could allow for optimization of oral bioavailability and metabolic stability, two long-standing challenges for this class.[10–12]

Methods:

Caution.

For the preparation of diazomethane, there is explosion and shock hazard. Needles should be avoided and unscratched glassware should be used. Perform reagent preparation, aqueous

workup, and all reactions in a well-ventilated fume hood behind a blast shield. All glassware and waste solutions should be quenched extremely carefully with dilute acid before removing from fume hood.

For the synthesis of cyanoester **18**, hydrocyanation product **S18**, and nitrile **S32** there is a cyanide hazard. Perform reaction, aqueous workup, and purification in a well-ventilated fume hood. All glassware and waste solutions should be washed with bleach prior to removing from fume hood.

MIC testing.

Compounds were evaluated by Micromyx LLC (Fig. 5) against a variety of pathogenic bacteria, using the broth microdilution method, as recommended by the Clinical and Laboratory Standards Institute (CLSI). Pre-weighed vials of the test agents were stored at −20 °C until testing. On the day of the assay, the compounds were dissolved in 100% DMSO (Sigma 472301) to a stock concentration of 1280 μg ml^{-1} or 640 μg ml^{-1}. The concentration range tested for each of the compounds was 32–0.03 μg ml^{-1} or 16–0.015 μg ml^{-1}, and each compound was tested in triplicate. Lefamulin and levofloxacin were used as the quality control agents. For more details on test organisms, medium and methods, see pgs. S8–S10 of the Supplementary Information.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgement.

Data availability statement:

All data are available in the main text or the Supplementary Information. Crystallographic data for the structures reported in this Article have been deposited at the Cambridge Crystallographic Data Centre, under deposition numbers CCDC 2114513 (**S3**), 2114514 (**19**), 2114515 (**26**), 2114516 (**S20**), and 2114517 (**S37**). Copies of the data can be obtained free of charge via https://www.ccdc.cam.ac.uk/structures/.

Main references.

1. Fazakerley NJ & Procter DJ Synthesis and synthetic chemistry of pleuromutilin. Tetrahedron 70, 6911–6930 (2014).

2. Goethe O, Heuer A, Ma X, Wang Z & Herzon SB Antibacterial properties and clinical potential of pleuromutilins. Nat. Prod. Rep. 36, 220–247 (2019). [PubMed: 29979463]

3. Davidovich C et al. Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity. Proc. Natl. Acad. Sci. U. S. A. 104, 4291–4296 (2007). [PubMed: 17360517]

4. Thirring K et al. Nabriva Therapeutics. Preparation of 12-*epi*-Pleuromutilin Derivatives as Antimicrobial Agents. WO2015110481A1 (2015).

5. Berner HV,H, Schulz G & Schneider H Inversion of configuration of the vinylgroup at carbon 12 by reversible retro-en-cleavage. Monatsh. fuer Chem. 117, 1073 (1986).

6. Wicha W et al. Efficacy of novel extended spectrum pleuromutilins against *E. coli* in vitro and in vivo. In 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark (2015).

7. Paukner S et al. In vitro activity of the novel pleuromutilin BC-3781 tested against bacterial pathogens causing sexually transmitted diseases (STD). In 53rd Interscience Conference on Antimicrob. Agents Chemother. Denver, CO, (2013).

8. Paukner S & Riedl R Pleuromutilins: Potent Drugs for Resistant Bugs—Mode of Action and Resistance. Cold Spring Harbor Perspect. Med. 7, a027110 (2017).

9. Gentry DR, Rittenhouse SF, McCloskey L & Holmes DJ Stepwise exposure of *Staphylococcus aureus* to pleuromutilins is associated with stepwise acquisition of mutations in *rpl*C and minimally affects susceptibility to retapamulin. Antimicrob. Agents Chemother. 51, 2048–2052 (2007). [PubMed: 17404009]

10. Springer DM et al. Synthesis and activity of a C-8 keto pleuromutilin derivative. Bioorg. Med. Chem. Lett. 13, 1751–1753 (2003). [PubMed: 12729657]

11. Fu L et al. Synthesis and antibacterial activity of C-2(S)-substituted pleuromutilin derivatives. Chin. Chem. Lett. 21, 507–510 (2010).

12. Sun F et al. Unraveling the Metabolic Routes of Retapamulin: Insights into Drug Development of Pleuromutilins. Antimicrob. Agents Chemother. 62, e02388–17 (2018). [PubMed: 29358298]

13. Daum RS, Kar S, Kirkpatrick P Retapamulin. Nat. Rev. Drug Discov. 6, 865–866 (2007).

14. Veve MP & Wagner JL Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic. Pharmacotherapy 38, 935–946 (2018). [PubMed: 30019769]

15. Liu F & Myers AG Development of a platform for the discovery and practical synthesis of new tetracycline antibiotics. Curr. Opin. Chem. Biol. 32, 48–57 (2016). [PubMed: 27043373]

16. Seiple IB et al. A platform for the discovery of new macrolide antibiotics. Nature 533, 338–345 (2016). [PubMed: 27193679]

17. Li Q et al. Synthetic group A streptogramin antibiotics that overcome Vat resistance. Nature 586, 145–150 (2020). [PubMed: 32968273]

18. Mitcheltree MJ, Stevenson JW, Pisipati A & Myers AG A Practical, Component-Based Synthetic Route to Methylthiolincosamine Permitting Facile Northern-Half Diversification of Lincosamide Antibiotics. J. Am. Chem. Soc. 143, 6829–6835 (2021). [PubMed: 33930268]

19. Gibbons EG Total synthesis of (±)-pleuromutilin. J. Am. Chem. Soc. 104, 1767–1769 (1982).

20. Boeckman RK, Springer DM & Alessi TR Synthetic studies directed toward naturally occurring cyclooctanoids. 2. A stereocontrolled assembly of (±)-pleuromutilin via a remarkable sterically demanding oxy-cope rearrangement. J. Am. Chem. Soc. 111, 8284–8286 (1989).

21. Fazakerley NJ, Helm MD & Procter DJ Total synthesis of (+)-pleuromutilin. Chem. – Eur. J. 19, 6718–6723 (2013). [PubMed: 23589420]

22. Murphy SK, Zeng M & Herzon SB A modular and enantioselective synthesis of the pleuromutilin antibiotics. Science, 356, 956 (2017). [PubMed: 28572392]

23. Zeng M; Murphy SK; Herzon SB Development of a Modular Synthetic Route to (+)-Pleuromutilin, (+)-12-*epi*-Mutilins, and Related Structures. J. Am. Chem. Soc. 139, 16377–16388 (2017). [PubMed: 29048164]

24. Farney EP; Feng SS; Schafers F; Reisman SE Total Synthesis of (+)-Pleuromutilin. J. Am. Chem. Soc. 140, 1267–1270 (2018). [PubMed: 29323492]

25. Lotesta SD et al. Expanding the pleuromutilin class of antibiotics by de novo chemical synthesis. Chem. Sci. 2, 1258–1261 (2011). [PubMed: 21874155]

26. Nagata W, Yoshioka M & Murakami M Hydrocyanation. VI. Application of the new hydrocyanation methods to conjugate hydrocyanation of α,β-unsaturated ketones, conjugated dienones, and conjugated enamines and to preparation of α-cyanohydrins. J. Am. Chem. Soc. 94, 4654–4672 (1972).

27. Egger H & Reinshagen H New pleuromutilin derivatives with enhanced antimicrobial activity. II. Structure-activity correlations. J. Antibiot (Tokyo) 29, 923–927 (1976). [PubMed: 993132]

28. Sarpong R, Su JT & Stoltz BM The Development of a Facile Tandem Wolff/Cope Rearrangement for the Synthesis of Fused Carbocyclic Skeletons. J. Am. Chem. Soc. 125, 13624–13625 (2003). [PubMed: 14599176]

29. Ireland RE & Willard AK The stereoselective generation of ester enolates. Tetrahedron Lett. 16, 3975–3978 (1975).

30. Justicia J, Sancho-Sanz I, Álvarez-Manzaneda E, Oltra JE & Cuerva JM Efficient Propargylation of Aldehydes and Ketones Catalyzed by Titanocene(III). Adv. Synth. Catal. 351, 2295–2300 (2009).

31. Bartolo ND, Read JA, Valentín EM & Woerpel KA Reactions of Allylmagnesium Reagents with Carbonyl Compounds and Compounds with C═N Double Bonds: Their Diastereoselectivities Generally Cannot Be Analyzed Using the Felkin–Anh and Chelation-Control Models. Chem. Rev. 120, 1513–1619 (2020). [PubMed: 31904936]

32. Muñoz-Bascón J, Sancho-Sanz I, Álvarez-Manzaneda E, Rosales A & Oltra JE Highly Selective Barbier-Type Propargylations and Allenylations Catalyzed by Titanocene(III). Chem. – Eur. J 18, 14479–14486 (2012). [PubMed: 22996150]

33. Frigerio M & Santagostino M A mild oxidizing reagent for alcohols and 1,2-diols: o-iodoxybenzoic acid (IBX) in DMSO. Tetrahedron Lett. 35, 8019–8022 (1994).

34. Montgomery J Nickel-Catalyzed Reductive Cyclizations and Couplings. Angew. Chem. Int. Ed. Engl. 43, 3890–3908 (2004). [PubMed: 15274210]

35. Tasker SZ, Standley EA & Jamison TF Recent advances in homogeneous nickel catalysis. Nature 509, 299–309 (2014). [PubMed: 24828188]

36. Crabtree RH, & Davis MW Directing effects in homogeneous hydrogenation with [Ir(cod)(PCy$_3$)(py)]PF$_6$. J. Org. Chem. 51, 2655–2661 (1986).

37. Wavefunction I Spartan 18, Irvine, CA.

38. Riedl RH, Heilmayer W & Spence L Nabriva Therapeutics. Process for the preparation for the preparation of Pleuromutilins. WO/2011/146954 (2011).

39. Lykkeberg AK, Cornett C, Halling-Sørensen B & Hansen SH Isolation and structural elucidation of tiamulin metabolites formed in liver microsomes of pigs. J. Pharm. Biomed. Anal. 42, 223–231 (2006). [PubMed: 16725295]

40. Lykkeberg AK, Halling-Sørensen B & Jensen LB Susceptibility of bacteria isolated from pigs to tiamulin and enrofloxacin metabolites. Vet. Microb. 121, 116–124 (2007).

41. Marx JN & Norman LR Synthesis of (–)-acorone and related spirocyclic sesquiterpenes. J. Org. Chem. 40, 1602–1606 (1975).

42. Ito Y, Hirao T & Saegusa T Synthesis of α,β-unsaturated carbonyl compounds by palladium(II)-catalyzed dehydrosilylation of silyl enol ethers. J. Org. Chem. 43, 1011–1013 (1978).

43. Shvo Y & Arisha AHI Regioselective Catalytic Dehydrogenation of Aldehydes and Ketones. J. Org. Chem. 63, 5640–5642 (1998).

44. Bell MG et al. Eli Lilly and Company. Pyrazole Derivatives Useful as Aldolsterone Synthase Inhibitors. WO 2012/173849 Al (2012).

45. Nakamura E, Matsuzawa S, Horiguchi Y & Kuwajima I Me$_3$SiCl accelerated conjugate addition of stoichiometric organocopper reagents. Tetrahedron Lett. 27, 4029–4032 (1986).

46. Ito Y, Fujii S & Saegusa T Reaction of 1-silyloxybicyclo[n.1.0]alkanes with iron(III) chlorides. A facile synthesis of 2-cycloalkenones via ring enlargement of cyclic ketones. J. Org. Chem. 41, 2073–2074 (1976).

47. Sammakia T, Jacobs JS Picolinic acid as a partner in the Mitsunobu reaction: Subsequent hydrolysis of picolinate esters under essentially neutral conditions with copper acetate in methanol. Tetrahedron Lett. 40, 2685–2688 (1999).

48. Richter MF et al. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature 545, 299–304 (2017). [PubMed: 28489819]

Fig. 1. The structures of (+) pleuromutilin (1), clinically relevant derivatives, and prior synthetic art.

a. Structures of (+)-pleuromutilin (**1**), 12-*epi*-pleuromutilin (**2**), retapamulin (**3**), lefamulin (**4**), and extended spectrum pleuromutilins (ESPs, **5**). **b.** Overview of the prior synthetic route to (+)-pleuromutilin (**1**) by Murphy et al.[18]

Fig. 2. An unexpected vinylogous Wolff rearrangement provided access to the C9 quaternary stereocenter and formed the basis for a synthetic route to C12 normethyl pleuromutilins.
a. Arndt–Eistert homologation of the α-diazoketone **11** provided the homologation product **12** and the rearrangement product **13**. **b.** Potential mechanistic pathways for the rearrangement may involve a concerted 2,3-rearrangement of the α-diazoketone **14** or rearrangement of the ketocarbene **16**. **c.** Synthesis of the C12 normethyl pleuromutilin derivative **24**. **d.** Proposed orientation of the (Z)-enolate **25**. **e.** X-ray structure of the mutilin derivative **26**. **f.** MMFF (Merck molecular force field) overlay of **1** and **24**.

Fig. 3. Scope of the butynylation reaction, competition of a fully derivatized analog and synthesis of a C7-substitued pleuromutilin.

a. Products synthesized by addition to **20**. Isolated yields and diastereoselectivity are reported. **b.** Synthesis of the C12 normethyl lefamulin derivative **37**. **c.** Synthesis of the C7-substituted derivative **45**.

Fig. 4. Preparation of pleuromutilin derivatives, including ring contractions in the six- and eight-membered rings.

a. Synthesis of the ring-contracted derivatives **51**, **55** and **56**; NOE enhancements supporting the relative stereochemistry of **48**, **50**, **52**, **53**, and **54** are indicated by arrows. **b.** Synthesis of the derivative **59**, which contains a seven-membered ring. NOE enhancements supporting the relative stereochemistry of **58** are indicated by arrows.

Fig. 5. Seventeen structurally-distinct derivatives were prepared and evaluated against a panel of Gram-positive and Gram-negative bacteria.

Fully synthetic pleuromutilins prepared using the synthetic platform that feature different core modifications (**24**, **37**, **45**, **63–72**), ring sizes (**51**, **55**, **56**, **59**) and C14 glycolic ester derivatives (R[1]–R[3]). The compounds were compared to semisynthetic controls (lefamulin (**4**), **60–62**; shown in the gray box) against a panel of Gram-positive and Gram-negative bacteria. Minimum Inhibitory Concentrations (µg/mL) are reported. MSSA: methicillin-susceptible *S. aureus*; MRSA: methicillin-resistant *S. aureus*; MRSE: methicillin-resistant

S. epidermidis; MSSE: methicillin-susceptible *S. epidermidis*; VSE: vancomycin-susceptible *Enterococcus*; VRE: vancomycin-resistant *Enterococcus*; PISP: penicillin-intermediate *S. pneumoniae*; PRSP: penicillin-resistant *S. pneumoniae*.